Introduction
============

The 18 kDa translocator protein (TSPO) is an outer mitochondrial membrane protein that has attracted increasing interest for its use as a PET imaging target to visualize inflammation in the brain. TSPO is expressed in many tissues, including the brain, and has been suggested to be involved in mitochondrial 'household' functions, although its exact functions are unknown ([@awz287-B92]; [@awz287-B90]; [@awz287-B64]; [@awz287-B73]; [@awz287-B18]). TSPO PET signal is markedly upregulated in neurodegenerative and neuroinflammatory diseases including multiple sclerosis ([@awz287-B92]; [@awz287-B90]; [@awz287-B64]; [@awz287-B73]; [@awz287-B18]), Alzheimer's disease ([@awz287-B25]; [@awz287-B96]), Parkinson's disease ([@awz287-B66]), viral encephalitis ([@awz287-B4]; [@awz287-B12]), amyotrophic lateral sclerosis ([@awz287-B81]), Huntington's disease ([@awz287-B59]) and frontotemporal dementia ([@awz287-B13]) and thus has become recognized as a marker of *in vivo* neuroinflammation ([@awz287-B5]; [@awz287-B88]; [@awz287-B15]). A limitation of these applications has been uncertainty regarding the interpretation of increased signal; many of the studies have widely assumed that increased signal reflects activated microglia, while ignoring the potential contributions of astrocytes and other cell types ([@awz287-B33]; [@awz287-B92]; [@awz287-B5]; [@awz287-B12]; [@awz287-B22]; [@awz287-B27], [@awz287-B30], [@awz287-B28], [@awz287-B29]; [@awz287-B38]; [@awz287-B82]; [@awz287-B79]; [@awz287-B80]; [@awz287-B87]; [@awz287-B70]; [@awz287-B31]; [@awz287-B95]). Although recent studies using animal models of neurodegenerative diseases have shown astrocytic TSPO ([@awz287-B53]; [@awz287-B74]; [@awz287-B3]; [@awz287-B42]; [@awz287-B58]; [@awz287-B46]; [@awz287-B20]; [@awz287-B23]; [@awz287-B93]; [@awz287-B47]; [@awz287-B78]; [@awz287-B24]; [@awz287-B41]; [@awz287-B63]), only a few have examined astrocytic expression of TSPO in the human CNS ([@awz287-B43]), and these descriptions have been qualitative rather than quantitative ([@awz287-B16]; [@awz287-B54]; [@awz287-B50]).

In experimental autoimmune encephalomyelitis and in cuprizone, two animal models of multiple sclerosis, increased TSPO expression has been described in astrocytes and microglia ([@awz287-B20]; [@awz287-B61]). Increased microglial TSPO expression is associated with pro-inflammatory markers in rodents ([@awz287-B6]). Based on animal model studies, TSPO has been suggested as a therapeutic target for modulation of the pathogenic microglial phenotypes ([@awz287-B20]; [@awz287-B72]). However, in humans, TSPO is not upregulated in either pro-inflammatory macrophages ([@awz287-B62]) or primary microglia ([@awz287-B67])*.* These *in vitro* data are consistent with the finding that monocytes isolated from people with multiple sclerosis show lower TSPO expression compared to healthy controls ([@awz287-B35]). Additionally, microglia/macrophages in multiple sclerosis lesions adopt an intermediate phenotype, and the classical M1 (pro-inflammatory) and M2 (anti-inflammatory) phenotypes probably represent extreme states only found *in vitro* ([@awz287-B68]). Thus, in contrast to the pattern of TSPO expression in rodent models, it may not be so specifically associated with pro-inflammatory microglia in multiple sclerosis ([@awz287-B97]). For interpretation of TSPO PET studies of brain inflammation in multiple sclerosis and for exploration of potential therapeutic targeting of TSPO, it is thus crucial to determine whether specific microglial markers are associated with TSPO expression and to what extent these cells contribute to the TSPO PET signal in neuroinflammatory diseases *in vivo*.

Here we have performed a quantitative neuropathological study in a large cohort of multiple sclerosis brain and spinal cord tissues to characterize the cell types and identify the phenotypes of microglia expressing TSPO in lesions in the white and grey matter. We report three important findings. First, we confirm previous data showing that TSPO expression is increased in active and chronic active lesions, and that HLA-DR+ microglia are the cell type responsible for the majority of the signal. However, astrocytes expressing TSPO in the centre of chronic active and in inactive lesions also are important contributors to the total number of TSPO+ cells. Second, we show that, in humans, TSPO reports on microglia density rather than relative microglial activation and polarization. Finally, we confirm a strong, direct relationship between TSPO expression and TSPO radioligand binding in brain tissue *ex vivo*.

Therefore, we show that while expression of TSPO reflects activated microglia, it is misleading to characterize TSPO as a marker restricted to pro-inflammatory microglia.

Materials and methods
=====================

Human brain tissue
------------------

Human brain tissue was obtained at autopsy from 42 patients with multiple sclerosis and 12 age-matched cases with no neurological disorders or peripheral inflammation. Biopsy material from MRI tumour-like lesions was taken from four patients with suspected multiple sclerosis. Patient data and clinical details are summarized in [Table 1](#awz287-T1){ref-type="table"}. The rapid autopsy regimen of the Netherlands Brain Bank in Amsterdam (coordinator Dr I. Huitinga) was used to acquire the samples, with the approval of the Medical Ethical Committee of the Amsterdam UMC. All participants or next of kin had given informed consent for autopsy and use of their tissues for research purposes. Tissue samples from multiple sclerosis cases were selected from regions of interest after *ex vivo* MRI ([@awz287-B21]; [@awz287-B8]). Brain samples were cut in half and fixed in 10% formalin and embedded in paraffin or snap-frozen and stored in liquid nitrogen. The cases and lesions were selected from a large cohort of multiple sclerosis cases based on the size and lesion type for quantitative analysis. Lesion stages were based on immunohistochemical detection for myelin proteolipid protein (PLP) to detect areas of myelin loss and expression of human leukocyte antigen DR (HLA-DR) ([@awz287-B84]; [@awz287-B44]). Briefly, active lesions were characterized by a focal area of myelin loss filled with myelin-laden 'foamy' macrophages; chronic active lesions were identified by a rim of activated microglia/macrophages surrounding a hypocellular centre, and inactive white matter lesions as a demyelinated area with few or no HLA-DR+ cells. The normal-appearing white (NAWM) and grey matter (NAGM) in the same tissue blocks from multiple sclerosis cases and control white and grey matter from age-matched controls were analysed as reference samples for the expression of cell markers.

###### 

Clinical details of multiple sclerosis and control cases

  Case              Age/gender      **Genotype** [^a^](#tblfn1){ref-type="table-fn"}   Diagnosis   Duration, years   PM delay, h:min               Cause of death
  -------------- ----------------- -------------------------------------------------- ----------- ----------------- ----------------- ----------------------------------------
  1                    69/F                                                            PPMS/SPMS         53               7:30         Respiratory failure with heart failure
  2                    70/F                                                            PPMS/SPMS         40               6:55                 Urine tract infection
  3                    50/M                                                            PPMS/SPMS         15               5:25                       Pneumonia
  4                    66/F                                                              SPMS            11               6:00                       Pneumonia
  5                    75/F                                                            PPMS/SPMS         24               5:00                     Heart failure
  6                    49/M                                                              SPMS            25               8:00                       Pneumonia
  7                    66/M                                                              SPMS            26               7:30                         Ileus
  8                    64/F                               Low                            SPMS            31               10:10               Urinary tract infection
  9                    61/M                               High                           SPMS            18               9:15                       Euthanasia
  10                   77/F                                                              PPMS            24               10:00                      Euthanasia
  11                   67/F                              Mixed                           SPMS            25               9:15                  Palliative sedation
  12                   45/M                                                              PPMS            10               7:45           Pulmonary embolism, cardiac arrest
  13                   59/F                                                              SPMS            24               4:45                       Euthanasia
  14                   58/F                                                              SPMS            36               10:40                      Euthanasia
  15                   44/M                                                              PPMS            21               10:15                   End stage of MS
  16                   51/M                                                              SPMS            19               11:00                       Unknown
  17                   57/F                               Low                            RRMS            26               8:40                       Urosepsis
  18                   57/F                               High                           PPMS            29               11:00                      Euthanasia
  19                   73/M                              Mixed                           RRMS            26               8:00                Urosepsis by advanced MS
  20                   76/F                               High                           SPMS            25               7:55                       Euthanasia
  21                   56/M                              Mixed                           PPMS            14               9:50                        Cachexia
  22                   74/M                              Mixed                           PPMS            15               10:15           Cardio-respiratory insufficiency
  23                   60/F                              Mixed                           SPMS             7               10:40                      Euthanasia
  24                   54/M                               Low                            PPMS            12               8:15                       Euthanasia
  25                   75/M                              Mixed                           PPMS            46               10:10                      Pneumonia
  26                   50/F                              Mixed                           SPMS            17               7:35                       Euthanasia
  27                   53/M                                                              SPMS            24               10:00                      Euthanasia
  28                   66/F                                                              PPMS            13               9:35                       Euthanasia
  29                   56/M                              Mixed                           SPMS            14               10:10                       Suicide
  30                   66/F                                                              SPMS            16               10:45                Pulmonary hypertension
  31                   81/F                                                              SPMS            31               4:35                       Pneumonia
  32                   63/M                                                              SPMS            25               8:15            Pneumonia, cachexia, dehydration
  33                   75/F                               High                           SPMS          Unknown            9:45                Fall, subdural haematoma
  34                   61/F                               High                          Unknown        Unknown            10:00                      Euthanasia
  35                   50/M                               Low                            SPMS            21               10:50                       Unknown
  36                   49/F                                                             Unknown        Unknown            8:30                        Unknown
  37                   50/F                                                              SPMS            18               9:05                       Euthanasia
  38                   57/M                                                              PPMS            24               10:15                        Sepsis
  39                   35/F                                                              SPMS            10               10:20                      Euthanasia
  40                   54/F                                                             Unknown          27               9:25                  Respiratory failure
  41                   67/M                                                              SPMS            38               11:00                     Sudden death
  42                   54/M                                                              SPMS            29               6:40                       Euthanasia
  **Biopsy**                                                                                                                          
  1                    51/M               Demyelinating disease, suspected MS                                                         
  2               Unknown/unknown         Demyelinating disease, suspected MS                                                         
  3                    27/M               Demyelinating disease, suspected MS                                                         
  4                    31/F               Demyelinating disease, suspected MS                                                         
  **Controls**                                                                                                                        
  1                    61/F                                                             Control          N/A              6:50                       Euthanasia
  2                    73/F                                                             Control          N/A              4:00         Lung fibrosis and renal insufficiency
  3                    67/M                                                             Control          N/A              4:30              Cardiac shock, organ failure
  4                    81/M                                                             Control          N/A              5:30                   Prostate carcinoma
  5                    67/M                                                             Control          N/A              18:35                Myocardial infarction
  6                    84/F                                                             Control          N/A              4:45                  Respiratory failure
  7                    91/F                                                             Control          N/A              7:45                  Decompensatio cordis
  8                    56/M                              Mixed                          Control          N/A              14:00                    Heart failure
  9                    92/F                                                             Control          N/A              7:00                      Acute death
  10                   62/M                              Mixed                          Control          N/A              7:20                        Unknown
  11                   49/M                              Mixed                          Control          N/A              6:15             Euthanasia, Hodgkin's lymphoma
  12                   51/M                                                             Control          N/A              7:30                       Euthanasia

Cases selected for autoradiography.

F = female; M = male; MS = multiple sclerosis; N/A = not applicable; PM = post-mortem; PP = primary progressive; RR = relapsing remitting; SP = secondary progressive.

###### 

Antibodies for immunohistochemistry

  Antigen                    Source            Antibody   Species       Dilution
  -------------------------- ---------------- ----------- ------------ ----------
  TSPO (PBR)                 Abcam             AB109497   Rabbit         1:750
  PLP                        Bio-Rad            MCA839G   Mouse          1:3000
  HLA-DR (LN3)               BioLegend          327011    Mouse          1:1000
  Vimentin                   Homemade             N/A     Mouse          1:6000
  GFAP                       Millipore          AB5541    Chicken        1:1000
  Olig2                      Millipore          AB9610    Rabbit         1:500
  CD3                        Agilent             A0452    Rabbit         1:1500
  CD20                       Agilent             M0755    Mouse          1:100
  TMEM119                    Merck             HPA051870  Rabbit         1:250
  P2RY12                     ANASPEC           AS55042A   Rabbit         1:200
  CD40                       Bio-Rad            MCA1590   Mouse           1:50
  Mannose receptor (CD206)   BD Biosciences     555953    Mouse           1:50
  S100β                      Merck               S2532    Mouse          1:200
  GLUT-1                     Merck              AB1783    Guinea pig     1:100

GLUT-1 = glucose transporter.

Immunohistochemistry
--------------------

Paraffin sections were de-paraffinized using xylene, rehydrated through descending alcohol solutions and washed in phosphate-buffered saline (PBS). Frozen sections were air-dried and fixed in 2% paraformaldehyde for 10 min at room temperature and washed in PBS. Endogenous peroxidase activity was blocked using 0.3% (w/v) H~2~O~2~. Following washing, paraffin sections underwent antigen retrieval in citrate or Tris/EDTA buffer in a water bath at 95°C for 30 min. After cooling, sections were washed and incubated in primary antibodies overnight in antibody diluent (Immunologic). After washing, sections were incubated in the appropriate secondary antibodies. Horseradish peroxidase labelled secondary antibodies were developed using 3,3′-diaminobenzidine (DAB, 1:50, DAKO) for 10 min after which sections were washed in Tris-buffered saline (TBS). Liquid permanent red (1:100, DAKO) was used to visualize alkaline phosphatase-labelled antibodies. Sections were washed with TBS, counterstained with haematoxylin, washed and mounted in Aquatex® (Merck). For immunofluorescence, sections were incubated with Alexa Fluor®-labelled secondary antibodies in antibody diluent for 90 min and nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). Appropriate negative controls were used by omitting the primary antibodies.

Image and statistical analyses
------------------------------

Images of each lesion type and randomly sampled areas of NAWM and NAGM, and white and grey matter from controls were collected with a Leica DC500 microscope (Leica Microsystems, Heidelberg, Germany) at x200 magnification. Fluorescent images were taken with a Leica TCS SP8 STED 3X confocal microscope. Pictures were analysed using ImageJ software and nuclei and positive cells were manually counted with the cell counter plugin (de Vos, University of Sheffield, UK). All nuclei except those within blood vessels were counted to determine the number of cells per field. Expression levels were analysed using TSPO+ pixels with a threshold of signal intensity that represented all DAB+ pixels per field. Inter-observer reporting was highly consistent, with a correlation coefficient of 0.98. Data were analysed using GraphPad Prism 7.02. All data were tested for normality distribution with the Shapiro-Wilk normality test. Differences between lesion types were analysed using ANOVA or Kruskal-Wallis analyses. When positive, Dunnett's *post hoc* analysis was performed to test the different groups to their respective NAWM or NAGM and control, corrected for multiple comparisons. Accordingly, white and grey matter from control cases were compared to NAWM and NAGM of multiple sclerosis tissue, respectively. Data was considered significant when *P \<* 0.05.

Genotyping
----------

DNA extraction and genotyping were performed on snap frozen brain samples (LGC Group Ltd.). In brief, following DNA extraction, the single nucleotide polymorphism-specific KASP^TM^ Assay mix and the universal KASP^TM^ Master mix were added to the DNA samples and placed in a thermal cycler for a minimum of 35 cycles, producing an allele-specific fluorescent signal in accordance with primers specific to rs6971 and rs6972. Each allele-specific primer produces a unique tail sequence that is associated with a fluorescent resonant energy transfer cassette, labelled with a FAM^TM^ dye, or HEX^TM^ dye. Plates were read on a BMG PHERAStar plate reader (BMG Labtech). In-house Kraken software was used to automatically identify genotypes, which were verified by staff at the LGC facility.

Autoradiography
---------------

Brain sections were prepared from frozen tissue blocks corresponding to the paraffin-embedded tissue blocks described above, allowing direct comparison of the same lesion for pathology and autoradiography. Sections were cut at 10 µm and thaw-mounted on standard glass microscope slides (VWR International Ltd.). Slides were dried for 30--60 min at room temperature and stored at −80°C. At the time of use, tissue had been stored for a maximum of 36 days. Prior to autoradiography, sections were thawed at room temperature for 15 min, washed for 20 min in assay buffer (50 mM Tris-HCl, pH 7.4 and incubated for 1 h in assay buffer containing the radioligand ^3^H-PK11195 \[1-(2-chlorophenyl)-*N*-methyl-*N*-(1-methylpropyl)-3-isoquinolinecarboxamide (Perkin Elmer, specific activity 82.7 Ci/mmol)\] and ^3^H-PBR28 {*N*-\[2-(methyloxy)phenyl\]methyl-*N*-\[4-(pheyloxy)-3-pyridinyl\] acetamide (Tritec, UK, specific activity 81 Ci/mmol)}. The concentrations were 1 nmol/l for ^3^H-PK11195 and 0.5 nmol/l for ^3^H-PBR28 as measured by liquid scintillation counting (Beckman LS 6500).

Adjacent sections were incubated with the radioligand and 10 µmol/l PK11195 (Tocris) to determine non-specific binding. Following incubation, sections were washed twice for 2 min each in washing buffer (50 mM Tris-HCl, pH 7.4, 4°C) on ice followed by 30 s in ice-cold ultra-pure water. All slides were air dried for 15--20 min and dehydrated for a minimum of 24 h in a sealed container in the presence of phosphorous pentoxide. Slides were then exposed to BAS-TR2040 imaging plates (Fuji Film) alongside ^3^H-standards (American Radiolabelled Chemicals) for 19 days. Imaging plates were scanned using a Typhoon FLA 7000 (GE) and analysed using Quantity One (Bio-Rad).

Autoradiography and genotyping analysis
---------------------------------------

Regions of interest were drawn around lesions, NAWM and NAGM on total binding images using immunohistochemical staining of adjacent sections as a reference. Corresponding regions of interest were drawn on the non-specific binding images for white and grey matter separately to determine the individual non-specific binding. A global background reading was obtained from a free area on the plate and subtracted from all other measurements. Radioligand signal from each area of non-specific binding was also subtracted from the corresponding ligand-bound section to eliminate non-specific signal. Radioactive concentrations were calculated from optical densities using a linear regression derived from the radioactive standards. Final values are expressed as fmol/mg tissue equivalent. The polymorphism rs6971 causes a single amino acid substitution at position 147 of TSPO, which has a substantial impact on the affinity with which PBR28 binds TSPO. The binding affinity of PBR28 for TSPO is reduced by a factor of ∼50 in subjects with threonine at position 147 (termed 'low affinity binders') relative to subjects with alanine at position 147 (termed 'high affinity binders'). Heterozygotes (termed 'mixed affinity binders') express both copies of TSPO (Ala147 and Thr147) and hence present both the high and low affinity binding sites in roughly equal proportion. Therefore, for a given expression level of the TSPO protein detected by immunohistochemistry, the ^3^H-PBR28 radioligand binding signal will be genotype dependent, showing rank order high affinity binders \> mixed affinity binders \> low affinity binders. Including all three genotypes in a correlation of the ^3^H-PBR28 signal with immunohistochemistry would therefore artificially weaken the correlation, and hence for this analysis, only high affinity binders were used. This phenomenon is not relevant for ^3^H-PK11195 as the affinity of this radioligand for TSPO is insensitive to the Thr147/Ala147 substitution.

Mean ligand binding for each region of interest was calculated. For sections containing multiple regions of interest for the same tissue type, the mean was calculated. Data were analysed using GraphPad Prism 7.02 (GraphPad Software, San Diego, CA). Data were tested for normality distribution with the Shapiro-Wilk normality test. Differences between lesions were analysed using a Kruskal-Wallis analysis with Dunnett's *post hoc* analysis and considered significant when *P \<* 0.05.

Data availability
-----------------

The data that support the findings of this study are available from the corresponding author on reasonable request.

Results
=======

Heterogeneity of TSPO+ cells in multiple sclerosis lesions
----------------------------------------------------------

Expression and localization of TSPO+ cells were investigated in NAWM and in active, chronic active and inactive white matter lesions from brains and spinal cord of people with multiple sclerosis and in control tissue from people who died of non-neurological diseases ([Fig. 1](#awz287-F1){ref-type="fig"}A--F). TSPO immunostaining had a punctate appearance across the cytoplasm of cells in both the controls and in cells from multiple sclerosis tissue, as is expected with a mitochondrial protein. The density of TSPO+ cells/mm^2^ was 5-fold greater in active white matter lesions (*P \<* 0.0001) and 4-fold greater in rims of chronic active brain lesions (*P =* 0.0001) compared to control white matter. Compared to NAWM, the density of TSPO+ cells was a mean of 2-fold higher for active lesions (*P =* 0.004) and chronic active lesions (*P =* 0.0170, [Fig. 1](#awz287-F1){ref-type="fig"}G).

![**Astrocyte and microglial expression of TSPO in white matter lesions.** Representative images of TSPO expression in control (**A** and **I**) and multiple sclerosis lesions (**B**--**F** and **I**--**N**); NAWM (**B** and **J**), active (**C** and **K**), chronic active (CA) rim (**D** and **L**) and centre (**E** and **M**), and inactive (**F** and **N**) lesions. Expression of TSPO in HLA-DR− cells (black arrowheads; insets **C**--**F**). Quantitative analysis of number of TSPO+ cells showed a significant increase up to five times in active and in the rim of chronic active lesions compared to control and NAWM (**G**). An 11- to 14-fold increase in TSPO+HLA-DR+ cells was found in active and the rim of chronic active lesions compared to control and NAWM (**H**). A 5-fold increase in TPSO+GFAP+ cells was found throughout all lesion stages compared to control and NAWM contributing up to 25% of the TSPO+ cells (**I**--**O**, insets). An overview of cellular TSPO signal of astrocytes and activated microglia macrophages (**P**) and oligodendrocytes (**P**, white arrowheads, inset). Representative images of astrocytic markers with TSPO expression in one multiple sclerosis lesion (**Q**--**T**). Biopsy material showing high TSPO expression in HLA-DR+ and GFAP+ cells (**U** and **V**, inset). \**P \<* 0.05; ^\*\*^*P \<* 0.01; ^\*\*\*^*P \<* 0.001; ^\*\*\*\*^*P \<* 0.0001. Scale bars in **A**--**F**, **I**--**N**, **P**, **U** and **V** = 50 μm; **Q**--**T** = 12.5 μm. Insets are digitally zoomed to ×800.](awz287f1){#awz287-F1}

We next investigated the characteristics of the TSPO+ cells. HLA-DR+ cells expressing TSPO were 11- to 14-fold more abundant in active lesions and chronic active lesion rims compared to the control white matter (active: *P =* 0.0220, chronic active rim: *P =* 0.0022; [Fig. 1](#awz287-F1){ref-type="fig"}H) and 16- to 21-fold greater than NAWM (active: *P =* 0.0196, chronic active rim: *P =* 0.0019, [Fig. 1](#awz287-F1){ref-type="fig"}H). TSPO+HLA-DR− cells with an astrocytic morphology expressing GFAP were found in all lesion subtypes ([Fig. 1](#awz287-F1){ref-type="fig"}I--N). Between 15- to 20-fold more TSPO+GFAP+ cells were observed in all lesion subtypes relative to control white matter (*P \<* 0.0001, [Fig. 1](#awz287-F1){ref-type="fig"}O). The relative number of TSPO+GFAP+ cells in lesions was 5- to 7-fold greater than in the NAWM (*P \<* 0.0001, [Fig. 1](#awz287-F1){ref-type="fig"}O).

HLA-DR+ microglia/macrophages expressing TSPO accounted for a mean of 40% of total TSPO+ cells in active lesions and in the rims of chronic active lesion ([Fig. 1](#awz287-F1){ref-type="fig"}P) and GFAP+ astrocytes constituted about 25% of TSPO+ cells in active lesions and in the rims of chronic active lesions. However, in the centre of chronic active and in inactive lesions TSPO+GFAP+ astrocytes represented as many as 65% of the TSPO+ cells although it must be emphasized that the centre of these lesions are hypocellular relative to the chronic lesion rims or the NAWM. In active lesion areas, a few cells were found co-expressing TSPO and OLIG2, an oligodendrocyte marker ([Fig. 1](#awz287-F1){ref-type="fig"}P, inset). TSPO+ astrocytes did not only co-localize with GFAP but also with vimentin, glut-1 and S100β ([Fig. 1](#awz287-F1){ref-type="fig"}Q--T). Most of the remaining fraction of TSPO+ cells that did not express HLA-DR or GFAP had microglial or macrophage morphology, but were not further characterized. To examine if the same is true of lesions in early multiple sclerosis, we used biopsy material from rapidly expanding active white matter lesions from four cases of multiple sclerosis. All samples also showed strong expression of TSPO in HLA-DR+ macrophages and microglia ([Fig. 1](#awz287-F1){ref-type="fig"}U), as well as in scattered GFAP+ astrocytes ([Fig. 1](#awz287-F1){ref-type="fig"}V).

Together, microglia and, to a lesser extent, astrocytes in multiple sclerosis lesions appeared to account for most of the TSPO+ cells in lesions and NAWM in the multiple sclerosis brains. TSPO+ vascular endothelial cells also were identified commonly but made up \<5% of the TSPO+ cells. Vascular TSPO expression patterns in multiple sclerosis lesions were not different from their expression in blood vessels of the NAWM and in control tissue.

TSPO expression in microglial phenotypes
----------------------------------------

To investigate whether TSPO expression in microglial cells defined a functionally specific phenotype, we tested for co-expression with more specific markers for microglia and their polarization. TMEM119 is reported to differentiate activated microglia from myeloid-derived macrophages and has been used to identify CNS-resident microglia. P2RY12 is a marker that identifies homeostatic microglia in normal white matter. Markers for pro-inflammatory (CD40) and anti-inflammatory (mannose receptor, CD206) activated microglia and macrophages also were used ([@awz287-B91]; [@awz287-B32]). Microglia/macrophages that express both CD40 and CD206 are described as having an intermediate phenotype. No significant differences were found in proportions of TMEM119+ microglia expressing TSPO across the lesion subtypes ([Fig. 2](#awz287-F2){ref-type="fig"}A--D). As reported previously ([@awz287-B97]), P2RY12+ cells expressing TSPO were substantially reduced in active lesions ([Fig. 2](#awz287-F2){ref-type="fig"}E--H). Numbers of macrophages and microglia showing an intermediate phenotype, and expressing TSPO were very low in control cases and were not detected in the NAWM in multiple sclerosis ([Fig. 2](#awz287-F2){ref-type="fig"}I and J). The density of microglia/macrophages with the intermediate phenotype represented 18% of the total TSPO+ cell population, in active lesions and in the rims of chronic active lesions ([Fig. 2](#awz287-F2){ref-type="fig"}J). By contrast, few TSPO+ microglia/macrophages with the intermediate phenotype were present in the centres of chronic active lesions or in inactive lesions, ([Fig. 2](#awz287-F2){ref-type="fig"}J). Cells that were solely expressing the pro-inflammatory marker CD40 or the anti-inflammatory mannose receptor CD206 always expressed TSPO, but were present in very low numbers in multiple sclerosis lesions (\<1% of total TSPO+ cells, data not shown). Thus, TSPO expression was not specifically associated with either solely pro- or anti-inflammatory microglia/macrophage phenotype based on these markers.

![**TSPO expression in microglial phenotypes and lymphocytes.** Resident microglia expressing TSPO in an active and chronic active lesion and the periplaque white matter (**A** and **B**) as well as in NAWM (**C**). Resident microglia did not show any significant difference in TSPO expression compared to control or NAWM (**D**). Overview of expression of the homeostatic marker P2RY12 with TSPO in an active and chronic active lesion and the periplaque white matter (**E** and **F**), as well as in NAWM (**G**). A loss in homeostatic microglia expressing TSPO was found in active and chronic active lesions stages (**H**). Both TSPO+ and TSPO− microglia were found expressing TMEM119 or P2RY12 in multiple sclerosis lesions (black arrowheads; insets; **C** and **G**). In contrast, active and chronic active lesions showed an increase in CD206+CD40+ cells expressing TSPO (**I** and **J**). T cells (CD3) showed low expression of TSPO in multiple sclerosis lesions (**K**) in contrast to B cells (CD20) which showed strong localization with TSPO (**L**). \**P \<* 0.05; ^\*\*^*P \<* 0.01; ^\*\*\*^*P \<* 0.001; ^\*\*\*\*^*P \<* 0.0001. Scale bars in **A**, **B**, **E** and **F** = 200 μm; **C**, **G**, **K** and **L** = 50 μm, **I** = 25 μm. Insets are digitally zoomed to ×800. CA = chronic active.](awz287f2){#awz287-F2}

TSPO expression in lymphocytes
------------------------------

Expression of TSPO in adaptive immune cells was investigated by double staining CD20+ B cells and CD3+ T cells in white matter lesions in multiple sclerosis ([Fig. 2](#awz287-F2){ref-type="fig"}K and L). The density of TSPO expression in CD3+ T cells was very low in all lesion types ([Fig. 2](#awz287-F2){ref-type="fig"}K) compared to expression by microglia. CD20+ B cells showed relatively stronger expression of TSPO in active ([Fig. 2](#awz287-F2){ref-type="fig"}L), chronic active and inactive lesion types. However, in the cases studied in this study T- and B-cell numbers were low in multiple sclerosis lesions and in the NAWM, and did not contribute significantly to the total number of TSPO+ cells (\<1% of total TSPO+ cells).

TSPO expression in multiple sclerosis lesions in the cortical grey matter and spinal cord
-----------------------------------------------------------------------------------------

Expression and localization of TSPO in the grey matter of multiple sclerosis brain was investigated in leukocortical, intracortical, subpial and transcortical lesions ([Fig. 3](#awz287-F3){ref-type="fig"}A--I) ([@awz287-B7]). No significant differences were found in the number of cells that express TSPO in grey matter lesions compared to NAGM or to control grey matter ([Fig. 3](#awz287-F3){ref-type="fig"}J). HLA-DR+ cells expressing TSPO were not significantly more abundant in the white and grey matter of leukocortical lesions than in the normal appearing white and grey matter or to control tissue ([Fig. 3](#awz287-F3){ref-type="fig"}K) and the density of TSPO+HLA-DR+ microglia was low compared to white matter lesions. We observed scattered GFAP+ astrocytes expressing TSPO only in the white matter of leukocortical lesions, similar to those found in purely white matter lesions ([Fig. 3](#awz287-F3){ref-type="fig"}C, inset).

![**TSPO expression in grey matter lesions.** Representative images of TSPO expression in control (**A** and **D**) and multiple sclerosis (**B**, **C** and **E**--**I**) in grey matter lesions; NAWM (**B**), and NAGM (**E**); leukocortical white matter (**C**), and grey matter (**F**); intracortical (**G**), subpial (**H**), and transcortical (**I**) lesions. Similar to white matter lesions leukocortical white matter lesions showed large TSPO+HLA-DR− cells (black arrowheads; **C**) which were GFAP+ astrocytes (**C**, inset). No differences were found in TSPO+ cells in grey matter lesions (**J**). No significant increase in TSPO+HLA-DR+ cells were found in grey matter lesions compared to control (**K**). Data are expressed as mean ± SEM. Scale bars in **A**--**I** = 50 μm. Insets are digitally zoomed to ×800. CON = control; GM = grey matter; LC = leukocortical; WM = white matter.](awz287f3){#awz287-F3}

The density of TSPO+ cells in the NAWM of the spinal cord was no greater than in control spinal cord white matter and neither was the TSPO+ cell density greater in white matter lesions in the spinal cord compared to NAWM or control white matter ([Fig. 4](#awz287-F4){ref-type="fig"}A--F). However, the density of TSPO+HLA-DR+ cells in active white matter lesions was approximately doubled relative to control white matter (*P =* 0.0324; [Fig. 4](#awz287-F4){ref-type="fig"}G). Active and chronic active lesions in the spinal cord also showed GFAP+ astrocytes expressing TSPO similar to the brain ([Fig. 4](#awz287-F4){ref-type="fig"}C and D, inset).

![**TSPO expression in white matter lesions in spinal cord.** Representative images of TSPO expression in control (**A**) and multiple sclerosis lesions (**B**--**F**); NAWM (**B**), active (**C**), chronic active (CA) rim (**D**) and centre (**E**), and inactive (**F**) lesions. Expression of TSPO was found in HLA-DR^−^ cells (black arrowheads; **C** and **D**). GFAP+ astrocytes expressing TSPO were also found in the spinal cord (**C**, inset). Quantitative analysis of the number of TSPO+ cells did not show significant differences between lesion types compared to control or NAWM (**G** and **H**). Increased expression of TSPO in HLA-DR+ cells was found in active lesions compared to NAWM (**I**). \**P* \< 0.05. Scale bars in **A**--**F** = 50 μm. Insets are digitally zoomed to ×800. A = active; CON = control.](awz287f4){#awz287-F4}

TSPO pixels and radioligand binding are increased in active lesions
-------------------------------------------------------------------

To investigate the relationship between TSPO expression and radioligand binding of ^3^H-PBR28 or ^3^H-PK11195, results from a pixel-based analysis of immunochemically-defined TSPO were integrated with TSPO radioligand autoradiography of white and grey matter lesions from sections in the same tissue blocks from multiple sclerosis and control brains ([Fig. 5](#awz287-F5){ref-type="fig"}). In white matter lesions, the number of TSPO+ pixels were increased by 5-fold compared to control white matter (active: *P \<* 0.0001; chronic active rim: *P =* 0.0003) and by 9-fold compared to NAWM (active: *P \<* 0.0001; chronic active rim: *P \<* 0.0001; [Fig. 6](#awz287-F6){ref-type="fig"}A). Endothelial TSPO expression contributed minimally (up to 8% in inactive lesions) to the amount of TSPO+ pixels in the white matter ([Supplementary Fig. 1A](#sup1){ref-type="supplementary-material"}).

![**Overview of ^3^H-PBR28 and ^3^H-PK11195 autoradiography of multiple sclerosis lesions.** Heat map in **A** ranges from low to high radioactivity (0.42 tissue equivalent nCi/mg to 16.23 tissue equivalent nCi/mg). Total binding of ^3^H-PBR28 (**A**, **G**, **M** and **S**), non-specific binding of ^3^H-PBR28 (**B**, **H**, **N** and **T**), total binding of ^3^H-PK11195 (**C**, **I**, **O** and **U**), non-specific binding of ^3^H-PK11195 (**D**, **J**, **P** and **V**), PLP (**E**, **K**, **Q** and **W**) and HLA-DR (**F**, **L**, **R** and **X**) images. LN3 staining denotes areas for active (red), chronic active (orange), inactive (purple) and subpial (pink) lesions, meninges (blue) and the grey and white matter border (dashed lines).](awz287f5){#awz287-F5}

![**^3^H-PBR28 and ^3^H-PK11195 autoradiography of multiple sclerosis lesions.** An increase in TSPO+ pixels was found in active and chronic active lesions compared to control and NAWM (**A**). ^3^H-PBR28 and ^3^H-PK11195 binding was increased in active white matter lesions and the centre of chronic active lesions (**B** and **C**). For grey matter lesions an increase was found in TSPO+ pixels in leukocortical lesion white matter and grey matter compared to their respective normal appearing tissue (**D**). Similar to white matter lesions ^3^H-PBR28 and ^3^H-PK11195 binding was increased in leukocortical lesion white matter areas (**E** and **F**). An increase in specific binding in NAGM relative to NAWM was found for ^3^H-PBR28. Mixed affinity binders (MAB) are depicted in grey while high affinity binders are depicted in black (HAB). Correlations were found for specific binding of ^3^H-PBR28 and ^3^H-PK11195 for both TSPO+ pixels per lesion and TSPO+ cells/mm^2^ (**G** and **H**). CA = chronic active; CON GM = control grey matter; CON WM = control white matter; LC = leukocortical lesion; TE = tissue equivalent.](awz287f6){#awz287-F6}

TSPO+ pixels were found to be increased markedly in the white matter component of leukocortical lesions relative to NAWM (*P \<* 0.0001, [Fig. 6](#awz287-F6){ref-type="fig"}D) and to control white matter (*P \<* 0.0001). A smaller increase in TSPO+ pixels was found in the grey matter (*P =* 0.0096) of leukocortical lesions relative to NAGM. However, no significant increase in TSPO+ pixels was found in other subtypes of grey matter lesions. Endothelial TSPO expression was decreased in grey matter lesions compared to the NAGM (*P \<* 0.005) and control grey matter (*P \<* 0.05, [Supplementary Fig. 1B](#sup1){ref-type="supplementary-material"}). Furthermore, endothelial TSPO expression was up to a 4-fold higher in the NAGM and control grey matter compared to NAWM (*P \<* 0.0001) and control white matter (*P =* 0.0033) in the brains of patients with multiple sclerosis ([Supplementary Fig. 1B](#sup1){ref-type="supplementary-material"}).

Specific tracer binding was calculated from ^3^H-PBR28 and ^3^H-PK11195 autoradiography in lesional and non-lesional areas of white and grey matter in the multiple sclerosis brains and in control tissue ([Fig. 5](#awz287-F5){ref-type="fig"}). No specific binding was found in four brains with low affinity binding genotypes for ^3^H-PBR28, identified by the rs6971 polymorphism. In all other cases, control white matter, NAWM and inactive lesions all showed relatively low binding of both ligands compared to active and chronic active lesions ([Fig. 6](#awz287-F6){ref-type="fig"}B and C). ^3^H-PBR28 binding was seven times greater in active lesions compared to control white matter (*P =* 0.0228) and three times greater than NAWM (*P =* 0.0064). Similarly, greater binding was found in the centres of chronic active lesions compared to NAWM (*P =* 0.0046) or control white matter (*P =* 0.0084, [Fig. 6](#awz287-F6){ref-type="fig"}B). ^3^H-PK11195 binding was approximately doubled in the active (*P =* 0.0006) and tripled in the chronic active centre (*P =* 0.0392) compared to NAWM ([Fig. 6](#awz287-F6){ref-type="fig"}C). In grey matter lesions ([Fig. 6](#awz287-F6){ref-type="fig"}E and F), binding was not greater for either ^3^H-PBR28 or ^3^H-PK11195 than in NAGM. An increased signal was found in the white matter of leukocortical lesions compared to control (*P =* 0.0414) for ^3^H-PBR28 or compared to NAWM (*P =* 0.0019) for ^3^H-PK11195. Specific binding in NAGM was more than tripled relative to NAWM for ^3^H-PBR28 (*P =* 0.0009).

A strong positive correlation between the pixel-based analysis of TSPO expression and specific binding of the ligand ^3^H-PBR28 was found (R^2^ = 0.5017, *P =* 0.0327), while only a trend was found for ^3^H-PK11195 (R^2^ = 0.4417, *P =* 0.0509, [Fig. 6](#awz287-F6){ref-type="fig"}G). Strong correlations were also found between the relative number of TSPO+ cells and specific binding for ^3^H-PBR28 (R^2^ = 0.4698, *P =* 0.0139) and ^3^H-PK11195 (R^2^ = 0.3229, *P =* 0.0271, [Fig. 6](#awz287-F6){ref-type="fig"}H).

Discussion
==========

TSPO is a marker of inflammation commonly attributed to microglial activation in neuroinflammatory and neurodegenerative diseases ([@awz287-B34]). Surprisingly, there has been very little data on which to base precise interpretations to date ([@awz287-B57]). Knowledge of the cellular and phenotypic correlates of the TSPO PET signal is important to better understand the clinical meaningfulness of the heterogeneity of TSPO PET radioligand uptake in T~2~-hyperintense lesions in multiple sclerosis before and after initiation of disease modifying therapies ([@awz287-B17]).

Here we have examined the expression and localization of TSPO in a large cohort of post-mortem multiple sclerosis in white and grey matter lesions of the brain and spinal cord. Similar to previous studies, TSPO expression was found in microglia in active and chronic active lesions ([@awz287-B16]; [@awz287-B56]; [@awz287-B45]; [@awz287-B51]; [@awz287-B43]). Similar to a recent study combining quantitative susceptibility mapping and immunohistochemistry ([@awz287-B43]), our studies revealed non-trivial expression of TSPO in astrocytes in all subtypes of lesions examined. The astrocytic TSPO accounted for ∼25% of the TSPO+ cells in active lesions or chronic active lesion rims and for 65% of the TSPO+ cells in the centres of chronic active and inactive lesions. Autoradiography using ^3^H-PBR28 and ^3^H-PK11195 revealed a strong correlation between TSPO+ cells and radioligand binding across all cell subtypes. This suggests that the TSPO PET signal arises from astrocytes as well as microglia, which is consistent with reports that newer generation ligands for TSPO bind to reactive astrocytes ([@awz287-B23]; [@awz287-B43]). Interpretation of the signal therefore needs to be context dependent. This finding is of clear importance for use of TSPO PET as an outcome measure in studies of modulation of these inflammatory processes.

While some studies have found reduced TSPO binding after anti-inflammatory treatments ([@awz287-B71]; [@awz287-B77]), it has also been suggested that current disease-modifying therapy may have a limited impact on microglial activity ([@awz287-B17]; [@awz287-B11]). However, as centres of chronic active and inactive lesions show increased expression of TSPO in reactive astrocytes, observations of TSPO expression alone are more ambiguous; treatment may reduce microglial density or activation without a reduction in TSPO PET signal, if astrocytic numbers increase simultaneously. The astrocytic contribution of the TSPO signal could also complicate differentiation of multiple sclerosis from leukodystrophies that have significant astrocytic but not microglial involvement ([@awz287-B83]).

While percentages of microglia in the grey matter have been reported to be significantly higher in white versus grey matter ([@awz287-B60]) an increase of radioligand binding in the NAGM compared to the NAWM was observed. This may be attributed to the increased contribution of TSPO+ endothelial cells due to the reported increased vascularity of grey verses white matter ([@awz287-B36]). That TSPO protein expression does not correlate with the PBR28 findings in the grey matter likely reflects the fundamentally different measurements of antibody binding (pixel counts) and autoradiography (ligand binding); the antibody detects the C terminus of the TSPO and autoradiography the binding of the ligand in the active site of the TSPO. Autoradiography has greater sensitivity because each molecule of radioligand contributes to the signal, whereas for immunohistochemistry a pixel is only TSPO+ if a threshold is reached. Hence when the levels of TSPO are low, and thus the signal of DAB positivity is very low, differences between autoradiography and the pixels counts may arise.

Increased TSPO expression was also observed in leukocortical lesions in multiple sclerosis but not in other grey matter lesions ([@awz287-B9]). This may well reflect the greater microglia and astrocyte activity in the white matter; pure cortical lesions in post-mortem tissues show little or no inflammation ([@awz287-B8]; [@awz287-B10]; [@awz287-B85]), although early lesions have been associated with prominent microglial activation ([@awz287-B52]). Leukocortical lesions, which can have a white matter inflammatory component, may show differences in behaviour with inflammatory processes diffusing into the cortical grey matter. Similar considerations may hold with active leptomeningeal inflammation ([@awz287-B40]; [@awz287-B1]). The spatial resolution of PET is low relative to cortical thickness, making confident assignment of TSPO PET signal to cortex (rather than adjacent white matter or meninges) problematic. While populations of patients undoubtedly show heterogeneity of grey matter pathology, our observations here raise questions about the interpretation of widespread TSPO PET signal in the cortical region as arising from cortical lesions ([@awz287-B69]), as opposed to meningeal ([@awz287-B40]) or leukocortical inflammation. Highly localized relative increases in TSPO signal in the cortex ([@awz287-B39]), may represent a rarer, relatively acute cortical lesion, rather than what is more typically defined post-mortem.

Increased TSPO expression also has been commonly attributed to activated microglia/macrophages and there is often an implication that the activation is pro-inflammatory ([@awz287-B34]). Recently, we have shown *in vitro* that, although TSPO gene and protein expression and TSPO radioligand binding increases in rodent microglia and macrophages with inflammatory stimulation, relative *TSPO* gene expression in human microglia and TSPO ligand binding in human monocyte-derived macrophages are reduced with pro-inflammatory activation ([@awz287-B67]). Here, we show that the increased TSPO expression in multiple sclerosis lesions primarily represents an intermediate activation state in which cells expressed both CD40 and CD206 ([@awz287-B91]; [@awz287-B68]); microglia solely expressing the pro-inflammatory marker CD40 or the anti-inflammatory marker mannose receptor CD206 were sparsely represented. This new observation thus confirms *in vitro* data suggesting that the TSPO expression signal does not distinguish between microglial phenotypes in human tissue ([@awz287-B67]). To the extent that increased TSPO PET signal can be used as a marker of microglia, it thus should be interpreted as reflecting increased microglial density rather than a change in activation state.

In principle, chronic active lesions showing a high expression of TSPO in the rims and a lower expression in the core could be distinguished from either active lesions that show high expression of TSPO throughout their volume or from inactive lesions with low cell density and low TSPO expression. Those chronic active lesions with increased rim TSPO expression might identify those that will expand slowly over time. The neuropathological active lesions with homogeneously high TSPO expression may define those most likely to decrease in volume over time ([@awz287-B76]; [@awz287-B26]). However, in practice, this discrimination could be confounded by the limited signal resolution of PET (typically 3--5 mm linearly) and consequent local signal averaging across commonly encountered lesions. This question deserves further investigations, e.g. by combining longitudinal MRI monitoring of the evolution of individual lesions with TSPO PET.

In the present study, TSPO expression in cells of the adaptive immune system was also investigated across the different lesion subtypes. A previous study has highlighted TSPO expression in several T-cell populations in blood ([@awz287-B35]), but our study did not find a strong expression of TSPO in T cells in the brain. On the other hand, we did see strong expression of TSPO in B cells in active, chronic active, and inactive lesions. However, lymphocyte numbers are low, so these contribute only a negligible amount to the total TSPO+ cells and thus will not influence the TSPO PET signal significantly.

TSPO expression in vascular endothelial cells in all blood vessels contributes to the diffuse TSPO PET signal in the healthy human brain ([@awz287-B89]). Moreover, the endothelial component of TSPO PET, which is dependent on the vascular density in the brain, differs between regions, and may change with ageing and pathology ([@awz287-B55]; [@awz287-B89]; [@awz287-B94]). We therefore investigated TSPO expression in endothelial cells by pixel count. In the white matter, endothelial TSPO expression did not contribute significantly to the total amount of TSPO expression (on average 5% of total TSPO pixels). However, as expected, we found an increase in endothelial contribution to TSPO expression relative to white matter as well as relative to grey matter lesions, which is consistent with the reported greater vascularity of grey verses white matter ([@awz287-B36]) and the hypo-cellularity of grey matter lesions ([@awz287-B7]).

The abundance of TSPO expression in astrocytes in the centres of chronic active lesions may suggest a more important role for TSPO in the pathophysiology of multiple sclerosis than previous data suggested ([@awz287-B16]). The human GFAP-driven conditional knockout of TSPO in mice resulted in significantly reduced severity of experimental autoimmune encephalomyelitis ([@awz287-B19]). In humans, activated microglia are capable of producing neurotoxic, reactive astrocytes in multiple sclerosis lesions ([@awz287-B49]). The apparent effects of TSPO ligands to reduce pathology in animal disease models could be mediated through effects on astrocytes ([@awz287-B75]; [@awz287-B86]). Similar to TSPO expression after cessation of lesion activity in multiple sclerosis, TSPO was found to be expressed long after recovery from experimental autoimmune encephalomyelitis and in cuprizone-mediated demyelination ([@awz287-B2]; [@awz287-B14]), implicating a role of TSPO in regenerative processes such as remyelinating lesions, possibly through production of neurotrophic factors such as pregnenolone and progesterone ([@awz287-B48]). These activities may be mediated by activated astrocytes.

There are limitations to our study suggesting future work. HLA-DR, Iba1 and CD68 are often used as markers for microglia interchangeably. Although these markers may be co-expressed, some Iba1+ and CD68+ cells do not express HLA-DR ([@awz287-B37]). This likely accounts for the TSPO+ cells with microglial morphology that did not express HLA-DR. These appear to constitute a fraction of up to 35% of the active lesions and the chronic active lesion rims, but confirmation of this is warranted. A more general problem is that characterization of the complexity of microglial/macrophage activation phenotypes well ideally demands use of more than one or two markers. Future work using cytokine expression assays and cell receptor markers simultaneously (e.g. using imaging mass cytometry) would add to their characterization.

In summary, our studies confirm that TSPO PET imaging provides a general marker of glial activation in multiple sclerosis, but emphasize that precise interpretations depend on the specific pathological context. With a single MRI scan, active, chronic active and inactive lesions cannot be distinguished well, leaving uncertainties regarding the interpretation of a paired TSPO PET scan. With other pathologies e.g. in Alzheimer's disease ([@awz287-B65]), the interpretation of increased TSPO PET signal also may reflect differences in relative abundance of microglia and astrocytes. Based on this and our previous work, we raise the possibility that a successful therapeutic intervention, which modulates the microglia from pro-inflammatory to neuroprotective or homeostatic phenotypes, might potentially have no effect on the TSPO PET signal, although interventions that reduce the density of activated glial cells may. Understanding the cellular neuropathology of TSPO expression quantitatively is a fundamental step in the evaluation of TSPO as a potential therapeutic target.
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